ByTrending Posts
Can Pfizer’s 2025 Earnings Reignite Confidence in Its…
Late January 2026 | Full-Year 2025 Earnings Preview | Big Pharma Strategy Reset Pfizer is set to report…
Will Novartis’ January 2026 Earnings Validate the Strength…
January 30, 2026 | Full-Year 2025 Earnings Preview | Innovative Medicines Outlook Novartis is scheduled to report its…
Will Roche’s 2025 Earnings Reset the Narrative for…
January 29, 2026 | Full-Year Earnings | Big Pharma Outlook Roche is set to publish its full-year 2025…
Why Is Roche Returning to China for Its…
January 2026 – Strategic Partnerships | China Biopharma | Oncology & ADCs Roche has extended its collaboration with…
Roche Signals Dual Growth Strategy: Price Reform Alignment…
January 2026 | Pharma & Policy | Bloomberg Interview Insight Roche is positioning itself for its next growth…
Can Amgen’s Strategic Partnerships Redefine Access and Growth…
23 January 2026 Executive Summary Amgen is actively exploring strategic collaborations with telehealth platforms and other access-focused partners…
Could Amgen’s 340B Pricing Practices Face Legal and…
23 January 2026 Executive Summary A healthcare advocacy group, Sagebrush, has filed a lawsuit against Amgen Inc., alleging…
Is Novo Nordisk Positioning Cell-Based Therapies as the…
23 January 2026 Executive Summary Novo Nordisk has expanded its strategic collaboration with Canadian biotech Aspect Biosystems, intensifying…
Is Novo Nordisk Facing Legal Scrutiny Over Diabetes…
23 January 2026 Executive Summary Novo Nordisk is facing a new class-action lawsuit in the U.S., filed by…
Trending Posts
Latest Stories
FDA’s AZ/GSK Biologics Rejections: Data Integrity Wake-Up or R&D Overhaul Catalyst?
FDA rejection letters issued March 3-4, 2026, flagged data integrity lapses in AstraZeneca’s subcutaneous tezepelumab…
Acadia’s Daybue CHMP Fight: $2B Rett Revenue at Stake or EMA Brick Wall?
Acadia Pharmaceuticals on March 3, 2026, fired back at CHMP’s rejection of Daybue (trofinetide) expansion…
Sanofi’s $1.53B Sino Biopharm Pact: Strategic Power Play or China-Derisked Bet?
Sanofi’s March 3, 2026, licensing of Sino Biopharm’s rovadicitinib—a JAK1 inhibitor approved in China for…
GLP-1s: The Thrilling Game-Changer in Obesity—Why Insurers Are Throwing Open the Reimbursement Gates
GLP-1 receptor agonists like semaglutide (Wegovy) and tirzepatide (Zepbound) are electrifying the obesity market with…
Gallery
